Alzheimers: Boosting brain protein may slow cognitive decline After analyzing the study data, researchers discovered that higher levels of Aβ42 after monoclonal antibody treatment were independently associated with slower cognitive impairment and
Exploring Alzheimer’s diseases with focus on diagnostic strategies . . . These complementary approaches enable comprehensive monitoring of Aβ42 dynamics across different stages of AD, offering promising avenues for early diagnosis, patient stratification, and targeted therapeutic intervention
Boosting brain protein levels may slow decline from Alzheimer’s They found that higher levels of Aβ42 after treatment were independently associated with slower cognitive impairment and clinical decline “All stories have two sides — even the one we have told ourselves about how anti-amyloid treatments work: by lowering amyloid,” Espay said
Alzheimer’s Decline May Be Slowed by Protein Boost What they found was that higher levels of Aβ42 after treatment were associated with slower cognitive decline "All stories have two sides—even the one we have told ourselves about how